MASH Claims Another Victim (Will This Disease Ever Get a Second Drug?)

BMS Bets Its Biggest Oral Drug Can Do More Than Clear Skin

Bristol Myers Squibb's Sotyktu faces a March 6 FDA decision that could push the oral TYK2 inhibitor beyond psoriasis and into the crowded psoriatic arthritis market. The drug's unusual mechanism offers a cleaner safety profile than rival oral options, and BMS is betting that difference matters.